Transcode Therapeutics (RNAZ) Assets (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Assets came in at $157.2 million in Q1 2026, up 1091.15% YoY from $13.2 million in Q1 2025, and down 3.22% on a QoQ basis from $162.4 million in Q4 2025.
Transcode Therapeutics (RNAZ) Assets (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Assets data on file, last reported at $157.2 million in Q1 2026.
- Quarterly Assets rose 1091.15% year-over-year to $157.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.2 million (up 1091.15% YoY) and the FY2025 annual result came in at $162.4 million, up 2126.32% from the prior year.
- Assets slipped to $157.2 million in Q1 2026, from $162.4 million in the prior quarter.
- In the past five years, Assets ranged from a high of $162.4 million in Q4 2025 to a low of $3.9 million in Q3 2024.
- A 5-year average of $26.4 million and a median of $7.6 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets slumped 70.34% — and 2025, when it jumped 2126.32%.
- Tracing RNAZ's Assets over 5 years: stood at $7.6 million in 2022, then slumped by 31.87% to $5.2 million in 2023, then jumped by 41.1% to $7.3 million in 2024, then jumped by 2126.32% to $162.4 million in 2025, then fell by 3.22% to $157.2 million in 2026.
- The last three Assets figures came in at $157.2 million (Q1 2026), $162.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 151.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.16 Mn |
| Dec 31, 2025 | 162.40 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 8.27 Mn |
| Mar 31, 2025 | 13.19 Mn |
| Dec 31, 2024 | 7.29 Mn |
| Sep 30, 2024 | 3.94 Mn |
| Jun 30, 2024 | 4.82 Mn |
| Mar 31, 2024 | 7.29 Mn |
| Dec 31, 2023 | 5.17 Mn |
| Sep 30, 2023 | 10.23 Mn |
| Jun 30, 2023 | 5.88 Mn |
| Mar 31, 2023 | 5.59 Mn |
| Dec 31, 2022 | 7.59 Mn |
| Sep 30, 2022 | 12.02 Mn |
| Jun 30, 2022 | 14.16 Mn |
| Mar 31, 2022 | 18.85 Mn |
| Dec 31, 2021 | 22.94 Mn |
| Sep 30, 2021 | 25.36 Mn |
| Jun 30, 2021 | 1.52 Mn |